文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

预防妊娠期疟疾的免疫策略:多利益相关方研讨会

Immunization strategies to prevent malaria in pregnancy - a multistakeholder workshop.
PubMed 文献 · Vaccine · 2026-03-25

作为ADVANCE-VAC4PM项目的一部分,欧洲疫苗倡议与FORS联合举办了关于使用疟疾疫苗预防妊娠期疟疾(MiP)的混合研讨会,汇集研究者、监管者、民间社会、全球卫生专家和政策制定者,讨论MiP疫苗的需求及开发、评估和实施策略。研讨会建议加强沟通与社区参与、定义关键试验疗效终点、强化药物警戒系统及早期监管协调。

要点

  • MiP疫苗应提供持久免疫,目标为青春期女孩和首次妊娠前女性。
  • 研讨会建议定义关键试验疗效终点并强化药物警戒系统。

核心结论

  • MiP疫苗有潜力补充现有疟疾控制策略,但需持续合作与国家投资以确保其成为全球疟疾预防的有效组成部分。

研究设计与样本

  • 多利益相关方混合研讨会,汇集研究者、监管者、民间社会、全球卫生专家和政策制定者。

主要发现

  • 胎盘疟疾(PM)是MiP相关疾病负担的主要原因,初产妇和二次妊娠妇女风险最高。
  • 靶向VAR2CSA抗原的PM疫苗候选(PRIMVAC和PAMVAC)正在开发中,现有预防感染的疟疾疫苗正被重新用于预防MiP。

关键数值与推荐

  • 研讨会建议加强沟通和社区参与策略。
  • 建议为关键临床试验定义相关疗效终点。
  • 建议强化药物警戒系统以支持安全性和真实世界有效性研究。
  • 建议规划早期监管协调。
  • 小组讨论强调利益相关方协调和减少剂量方案以支持未来MiP疫苗规划可行性。

临床怎么用

  • MiP疫苗应目标青春期女孩和首次妊娠前女性,以提供持久免疫。
  • 实施需加强沟通、社区参与和药物警戒系统。

局限性

  • 对MiP特异性负担的认识有限、药物警戒系统薄弱和疫苗犹豫可能阻碍未来疫苗实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As part of the ADVANCE-VAC4PM project, the European Vaccine Initiative (EVI) and La Fondation pour la Recherche Scientifique (FORS) co-hosted a hybrid workshop titled "Strategies for using malaria vaccines to prevent malaria in pregnancy (MiP)". The event brought together researchers, regulators, civil society, global health experts, and policymakers to discuss the need for MiP vaccines and strategies for their development, evaluation, and implementation. Malaria remains a major global health threat, with sub-Saharan Africa bearing the highest burden. Pregnant women (PW) are highly vulnerable, with an estimated 12.4 million affected in 2023. Beyond maternal health effects, a major cause of the MiP-related disease burden is placental malaria (PM), which can cause significant morbidity in newborns. PM risk is greatest in primigravidae and secundigravidae, as immunity develops over successive pregnancies. As existing malaria control strategies remain insufficient, MiP vaccines have the potential to complement them by eliciting immunity comparable to that seen in multigravidae. To be effective, such a vaccine should provide long-lasting immunity and target adolescent girls and women before their first pregnancy. PM vaccine candidates targeting the VAR2CSA antigen (PRIMVAC and PAMVAC) are in development, and existing malaria vaccines preventing infection are being repurposed to prevent MiP. However, limited awareness of MiP-specific burden, weak pharmacovigilance systems, and vaccine hesitancy may hinder future vaccine implementation. Key recommendations highlighted during the workshop included strengthening communication and community engagement strategies, defining relevant efficacy endpoints for pivotal clinical trials, reinforcing pharmacovigilance systems to support safety and real-world effectiveness studies, and planning for early regulatory alignment. Panel discussions emphasized the importance of stakeholder coordination and reduced-dose schedules to support future MiP vaccine programmatic feasibility. The workshop concluded with a call for sustained collaboration and national investment to ensure that MiP vaccines become a viable and effective component of global malaria prevention efforts.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. D'Alessio F, Honkpehedji J, Sirima S, et al. Immunization strategies to prevent malaria in pregnancy - a multistakeholder workshop. Vaccine. 2026. PMID: 41887022. doi:10.1016/j.vaccine.2026.128505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。